Our multi-disciplinary translational prostate cancer research group aims to transform the lives of patient cancer sufferers. In partnership with CUH surgical, oncology, pathology and radiology departments, we have performed ‘window of opportunity’ early phase trials, to explore in vivo effects of novel therapies of interest.
We have recently completed the Olaparib/anti-androgen window study (NCT02324998), and now as an AstraZeneca Partner of Choice, will be exploring how the effects of combination therapy in patient tissues. This invaluable platform provides a unique window in which to explore matched pre- and post-treatment tissue responses, in otherwise treatment-naïve early disease, and define mechanisms of action, biomarkers of response, and invaluable clinical insights into the effects of emerging therapies in earlier disease settings.
We have recently completed the Olaparib/anti-androgen window study (NCT02324998), and now as an AstraZeneca Partner of Choice, will be exploring how the effects of combination therapy in patient tissues. This invaluable platform provides a unique window in which to explore matched pre- and post-treatment tissue responses, in otherwise treatment-naïve early disease, and define mechanisms of action, biomarkers of response, and invaluable clinical insights into the effects of emerging therapies in earlier disease settings.
